Alopecia areata (AA) is an autoimmune disease characterized by acute, non-scarring, sharply demarcated hair loss of varying sizes. While not life-threatening, it significantly impacts individuals' daily lives and poses a considerable psychological burden. The etiology of AA is not fully understood, with genetic, environmental factors, and certain comorbidities playing roles in its pathogenesis. Treatment of AA is challenging, with responses varying greatly among individuals. However, there is a relatively extensive range of therapeutic options available. The document provides a brief overview of the disease's etiopathogenesis, prevention possibilities, and therapeutic options.
148 citations
,
March 2022 in “The New England Journal of Medicine” Baricitinib was effective in treating alopecia areata in two major trials.
7 citations
,
November 2018 in “British Journal of Dermatology” Alopecia areata is caused by immune system issues, and JAK inhibitors might help treat it.
191 citations
,
May 2018 in “British journal of dermatology/British journal of dermatology, Supplement” Alopecia areata is likely an autoimmune disease with unclear triggers, involving various immune cells and molecules, and currently has no cure.
44 citations
,
November 2016 in “Journal of The American Academy of Dermatology” The updated SALT II tool offers a more precise way to measure scalp hair loss.
144 citations
,
July 2015 in “Clinical, Cosmetic and Investigational Dermatology” Alopecia areata is a common autoimmune disease affecting about 2% of people, causing significant disability and often associated with mental health issues and other autoimmune conditions.
253 citations
,
December 2007 in “Journal of Investigative Dermatology” Hair follicles prevent NK cell attacks to avoid hair loss.
April 2019 in “International journal of research in dermatology” A child with rough nails also had hair loss and allergies.
